重度哮喘-话题@MedSci

#重度哮喘#

20篇内容 | 758人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1663694, encodeId=556016636944f, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=Allergy：重度哮喘T2生物标志物与微生物组成, objectType=article, longId=731371, objectId=460be31371b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460be31371b6, replyNumber=0, likeNumber=43, createdTime=2022-08-13, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460be31371b6, moduleTitle=Allergy：重度哮喘T2生物标志物与微生物组成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460be31371b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663692, encodeId=5939166369278, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=N Engl J Med：重度哮喘的生物治疗, objectType=article, longId=294730, objectId=f516294e303e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f516294e303e, replyNumber=0, likeNumber=0, createdTime=2022-05-09, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f516294e303e, moduleTitle=N Engl J Med：重度哮喘的生物治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f516294e303e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663691, encodeId=71b6166369141, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=NEJM：度匹鲁单抗治疗未控制的中重度哮喘儿童效果分析, objectType=article, longId=221769, objectId=f859221e69eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f859221e69eb, replyNumber=0, likeNumber=31, createdTime=2021-12-18, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f859221e69eb, moduleTitle=NEJM：度匹鲁单抗治疗未控制的中重度哮喘儿童效果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f859221e69eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663689, encodeId=c3d6166368950, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=NEJM：白细胞介素-33单抗Itepekimab可降低重度哮喘患者哮喘病情失控风险, objectType=article, longId=219621, objectId=c0f921962192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f921962192, replyNumber=0, likeNumber=36, createdTime=2021-12-27, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f921962192, moduleTitle=NEJM：白细胞介素-33单抗Itepekimab可降低重度哮喘患者哮喘病情失控风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0f921962192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663693, encodeId=ff91166369395, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=NEJM：患者自主激素吸入方案可降低中重度哮喘患者恶化风险, objectType=article, longId=299892, objectId=1a6829989271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a6829989271, replyNumber=0, likeNumber=40, createdTime=2022-07-04, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a6829989271, moduleTitle=NEJM：患者自主激素吸入方案可降低中重度哮喘患者恶化风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a6829989271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663690, encodeId=e177166369054, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=横断面研究：重度哮喘和COPD护理者的需求和生活质量, objectType=article, longId=219439, objectId=6917219439fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6917219439fe, replyNumber=0, likeNumber=55, createdTime=2021-11-05, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6917219439fe, moduleTitle=横断面研究：重度哮喘和COPD护理者的需求和生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6917219439fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663687, encodeId=508f166368e20, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=JAMA：3D vs 2D方案用于持续性中重度哮喘的治疗, objectType=article, longId=213144, objectId=872021314433, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=872021314433, replyNumber=0, likeNumber=49, createdTime=2021-10-15, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=872021314433, moduleTitle=JAMA：3D vs 2D方案用于持续性中重度哮喘的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=872021314433)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663688, encodeId=5e80166368837, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响, objectType=article, longId=214141, objectId=513b21414187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=513b21414187, replyNumber=0, likeNumber=38, createdTime=2021-08-19, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=513b21414187, moduleTitle=Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=513b21414187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, objectType=article, longId=208679, objectId=00752086e9b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00752086e9b6, replyNumber=0, likeNumber=42, createdTime=2021-06-05, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00752086e9b6, moduleTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00752086e9b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663685, encodeId=da36166368597, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=Thorax：激素避孕药与重度哮喘加重风险的关系, objectType=article, longId=203791, objectId=f526203e91e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f526203e91e0, replyNumber=0, likeNumber=51, createdTime=2021-06-07, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f526203e91e0, moduleTitle=Thorax：激素避孕药与重度哮喘加重风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f526203e91e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663684, encodeId=7ada166368479, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘, objectType=article, longId=151494, objectId=a936151494c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a936151494c3, replyNumber=0, likeNumber=41, createdTime=2019-06-20, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a936151494c3, moduleTitle=赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a936151494c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663681, encodeId=49bb166368147, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估, objectType=article, longId=138764, objectId=dc65138e6490, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc65138e6490, replyNumber=0, likeNumber=61, createdTime=2019-03-30, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc65138e6490, moduleTitle=Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc65138e6490)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状, objectType=article, longId=149158, objectId=7a4f149158de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a4f149158de, replyNumber=0, likeNumber=0, createdTime=2019-07-12, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a4f149158de, moduleTitle=2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a4f149158de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663680, encodeId=3cb91663680f1, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=Lancet Public Health：禁烟使儿童肺炎入院率降低18.5%，重度哮喘发作减少9.8%，早产儿减少3.7%, objectType=article, longId=130877, objectId=6d2e1308e7fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d2e1308e7fc, replyNumber=0, likeNumber=37, createdTime=2018-07-20, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d2e1308e7fc, moduleTitle=Lancet Public Health：禁烟使儿童肺炎入院率降低18.5%，重度哮喘发作减少9.8%，早产儿减少3.7%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d2e1308e7fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663682, encodeId=d986166368277, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=NEJM：Dupilumab对皮质激素依赖性重度哮喘患者的疗效显著, objectType=article, longId=138823, objectId=59661388231b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59661388231b, replyNumber=0, likeNumber=47, createdTime=2018-08-20, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59661388231b, moduleTitle=NEJM：Dupilumab对皮质激素依赖性重度哮喘患者的疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59661388231b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663679, encodeId=d75516636e998, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=Clin Exp Allergy：重度哮喘患者对口服泼尼松龙的反应与皮质类固醇程度有关！, objectType=article, longId=100708, objectId=3697100e08c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3697100e08c2, replyNumber=0, likeNumber=44, createdTime=2018-01-19, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3697100e08c2, moduleTitle=Clin Exp Allergy：重度哮喘患者对口服泼尼松龙的反应与皮质类固醇程度有关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3697100e08c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663678, encodeId=fed316636e824, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=Lancet：Benralizumab可安全有效治疗病情不受控制的重度哮喘患者（SIROCCO）, objectType=article, longId=76696, objectId=ddb3e669610, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb3e669610, replyNumber=0, likeNumber=37, createdTime=2017-04-25, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb3e669610, moduleTitle=Lancet：Benralizumab可安全有效治疗病情不受控制的重度哮喘患者（SIROCCO）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb3e669610)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663677, encodeId=ebbe16636e7ad, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=重度哮喘的定义、评估和治疗, objectType=article, longId=34810, objectId=0a373481083, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a373481083, replyNumber=0, likeNumber=35, createdTime=2014-07-29, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a373481083, moduleTitle=重度哮喘的定义、评估和治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a373481083)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663676, encodeId=0e0e16636e679, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=Am J Respir Crit Care Med：Brodalumab对中-重度哮喘无治疗作用, objectType=article, longId=27934, objectId=ca992e934cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca992e934cd, replyNumber=0, likeNumber=32, createdTime=2014-02-03, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca992e934cd, moduleTitle=Am J Respir Crit Care Med：Brodalumab对中-重度哮喘无治疗作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca992e934cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1663675, encodeId=8f0d16636e55c, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, objectTitle=抗胆碱能药物噻托溴铵治疗中度至重度哮喘存在争议, objectType=article, longId=20751, objectId=36b120e5173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36b120e5173, replyNumber=0, likeNumber=48, createdTime=2013-10-15, rootId=0, userName=小几洁, userId=1f5b25663198, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36b120e5173, moduleTitle=抗胆碱能药物噻托溴铵治疗中度至重度哮喘存在争议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36b120e5173)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

重度哮喘

2020-05-29

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

Allergy：重度哮喘T2生物标志物与微生物组成

2022-08-13

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

N Engl J Med：重度哮喘的生物治疗

2022-05-09

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

NEJM：度匹鲁单抗治疗未控制的中重度哮喘儿童效果分析

2021-12-18

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

NEJM：白细胞介素-33单抗Itepekimab可降低重度哮喘患者哮喘病情失控风险

2021-12-27

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

NEJM：患者自主激素吸入方案可降低中重度哮喘患者恶化风险

2022-07-04

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

横断面研究：重度哮喘和COPD护理者的需求和生活质量

2021-11-05

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

JAMA：3D vs 2D方案用于持续性中重度哮喘的治疗

2021-10-15

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响

2021-08-19

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始

2021-06-05

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

Thorax：激素避孕药与重度哮喘加重风险的关系

2021-06-07

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘

2019-06-20

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估

2019-03-30

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状

2019-07-12

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

Lancet Public Health：禁烟使儿童肺炎入院率降低18.5%，重度哮喘发作减少9.8%，早产儿减少3.7%

2018-07-20

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

NEJM：Dupilumab对皮质激素依赖性重度哮喘患者的疗效显著

2018-08-20

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

Clin Exp Allergy：重度哮喘患者对口服泼尼松龙的反应与皮质类固醇程度有关！

2018-01-19

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

Lancet：Benralizumab可安全有效治疗病情不受控制的重度哮喘患者（SIROCCO）

2017-04-25

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

重度哮喘的定义、评估和治疗

2014-07-29

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

Am J Respir Crit Care Med：Brodalumab对中-重度哮喘无治疗作用

2014-02-03

小几洁 (审核中...)

前往app查看评论内容

#重度哮喘#

抗胆碱能药物噻托溴铵治疗中度至重度哮喘存在争议

2013-10-15

科室
- - 订阅+
  - 更多科室
工具
服务